ESPR
Price
$1.31
Change
-$0.08 (-5.76%)
Updated
Apr 3, 02:37 PM (EDT)
Capitalization
495.94M
40 days until earnings call
SUPN
Price
$32.82
Change
+$1.14 (+3.60%)
Updated
Apr 2 closing price
Capitalization
1.84B
40 days until earnings call
Ad is loading...

ESPR vs SUPN

Header iconESPR vs SUPN Comparison
Open Charts ESPR vs SUPNBanner chart's image
Esperion Therapeutics
Price$1.31
Change-$0.08 (-5.76%)
Volume$1.32K
Capitalization495.94M
Supernus Pharmaceuticals
Price$32.82
Change+$1.14 (+3.60%)
Volume$373.15K
Capitalization1.84B
ESPR vs SUPN Comparison Chart
Loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESPR vs. SUPN commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a StrongBuy and SUPN is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ESPR: $1.39 vs. SUPN: $32.82)
Brand notoriety: ESPR and SUPN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ESPR: 105% vs. SUPN: 59%
Market capitalization -- ESPR: $495.94M vs. SUPN: $1.84B
ESPR [@Pharmaceuticals: Other] is valued at $495.94M. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.84B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • ESPR’s FA Score: 0 green, 5 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, both ESPR and SUPN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 4 TA indicator(s) are bullish while SUPN’s TA Score has 4 bullish TA indicator(s).

  • ESPR’s TA Score: 4 bullish, 4 bearish.
  • SUPN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SUPN is a better buy in the short-term than ESPR.

Price Growth

ESPR (@Pharmaceuticals: Other) experienced а -14.72% price change this week, while SUPN (@Pharmaceuticals: Other) price change was +1.52% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.81%. For the same industry, the average monthly price growth was +65.47%, and the average quarterly price growth was -10.24%.

Reported Earning Dates

ESPR is expected to report earnings on May 13, 2025.

SUPN is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-2.81% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($1.84B) has a higher market cap than ESPR($496M). SUPN YTD gains are higher at: -9.237 vs. ESPR (-36.818). SUPN has higher annual earnings (EBITDA): 90M vs. ESPR (-150.11M). SUPN has more cash in the bank: 255M vs. ESPR (82.2M). SUPN has less debt than ESPR: SUPN (41.5M) vs ESPR (266M). SUPN has higher revenues than ESPR: SUPN (608M) vs ESPR (116M).
ESPRSUPNESPR / SUPN
Capitalization496M1.84B27%
EBITDA-150.11M90M-167%
Gain YTD-36.818-9.237399%
P/E RatioN/A1677.00-
Revenue116M608M19%
Total Cash82.2M255M32%
Total Debt266M41.5M641%
FUNDAMENTALS RATINGS
ESPR vs SUPN: Fundamental Ratings
ESPR
SUPN
OUTLOOK RATING
1..100
557
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
10078
PRICE GROWTH RATING
1..100
8972
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for SUPN (71) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew somewhat faster than SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for ESPR (100) in the Biotechnology industry. This means that SUPN’s stock grew somewhat faster than ESPR’s over the last 12 months.

SUPN's SMR Rating (78) in the Pharmaceuticals Other industry is in the same range as ESPR (100) in the Biotechnology industry. This means that SUPN’s stock grew similarly to ESPR’s over the last 12 months.

SUPN's Price Growth Rating (72) in the Pharmaceuticals Other industry is in the same range as ESPR (89) in the Biotechnology industry. This means that SUPN’s stock grew similarly to ESPR’s over the last 12 months.

SUPN's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ESPR (100) in the Biotechnology industry. This means that SUPN’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRSUPN
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
66%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 10 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 22 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
62%
View a ticker or compare two or three
Ad is loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCBAX13.74N/A
N/A
BlackRock Large Cap Focus Value Inv C
MSFHX19.30N/A
N/A
MFS Total Return R3
WRLDX36.78N/A
N/A
Scharf Global Opportunity Institutional
JIHIX17.33N/A
N/A
JPMorgan International Hedged Equity I
NWAMX34.05N/A
N/A
Nationwide BNY Mellon Dyn US Eq Inc K

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and PTPI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and PTPI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
-1.42%
PTPI - ESPR
29%
Poorly correlated
-14.29%
ALKS - ESPR
28%
Poorly correlated
+0.37%
ZOMDF - ESPR
26%
Poorly correlated
-10.38%
EVO - ESPR
26%
Poorly correlated
-3.29%
VTRS - ESPR
25%
Poorly correlated
+0.70%
More

SUPN and

Correlation & Price change

A.I.dvisor tells us that SUPN and DVAX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SUPN and DVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+3.60%
DVAX - SUPN
30%
Poorly correlated
+1.26%
SNDL - SUPN
27%
Poorly correlated
N/A
ACET - SUPN
27%
Poorly correlated
-1.50%
ESPR - SUPN
26%
Poorly correlated
-1.42%
MKKGY - SUPN
24%
Poorly correlated
+0.48%
More